All In Biotech

Drug Trial Radar · NCT05642182

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

A Study of Improvement in Psoriasis Symptoms Associated with Combinations of Biologically Active Natural Substances (SFA-002) with Known Safety Profile

Last checked: Nov 19, 2026Latest source record: Jan 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Mar 31, 2022

Primary completion

Jul 30, 2025

Study completion Jul 31, 2025

Sponsor

Lead sponsor
SFA TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.

Conditions

  • Psoriasis

Interventions

  • SFA002Drug

    Study drug formula without excipient

  • SFA002Drug

    Study Drug SFA002 with excipient (Propionate)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Psoriasis Area and Severity Index (PASI) ScoreTime frame: From enrollment to final visit at 24 weeks treatment and 4 week follow-up

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • NuLine Clinical Trial Center

    Pompano Beach, Florida · Recruiting

  • Axis Clincals USA/ Red River Research Patners. LLC

    Fargo, North Dakota · Recruiting

  • Temple University

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.